Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Retinopathy Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Retinopathy Overview | 8 | 1 |
| Pipeline Products for Retinopathy Comparative Analysis | 9 | 1 |
| Retinopathy Therapeutics under Development by Companies | 10 | 1 |
| Retinopathy Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Retinopathy Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Retinopathy Products under Development by Companies | 15 | 1 |
| Retinopathy Products under Investigation by Universities/Institutes | 16 | 1 |
| Retinopathy Companies Involved in Therapeutics Development | 17 | 8 |
| Acucela Inc. | 17 | 1 |
| Biomar Microbial Technologies | 18 | 1 |
| Biophytis SAS | 19 | 1 |
| Edison Pharmaceuticals, Inc. | 20 | 1 |
| F. Hoffmann-La Roche Ltd. | 21 | 1 |
| Insmed Incorporated | 22 | 1 |
| Navigen Pharmaceuticals, Inc. | 23 | 1 |
| RedHill Biopharma Ltd. | 24 | 1 |
| Retinopathy Therapeutics Assessment | 25 | 9 |
| Assessment by Monotherapy Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 2 |
| Assessment by Molecule Type | 32 | 2 |
| Drug Profiles | 34 | 28 |
| ABC-294640 - Drug Profile | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 3 |
| AP-202 - Drug Profile | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| BIO-201 - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| BIO-203 - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| emixustat hydrochloride - Drug Profile | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 2 |
| IB-09A0133 - Drug Profile | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| IB-12A157 - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| mecasermin rinfabate (recombinant) - Drug Profile | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 3 |
| NAV-2729 - Drug Profile | 47 | 1 |
| Product Description | 47 | 1 |
| Mechanism of Action | 47 | 1 |
| R&D Progress | 47 | 3 |
| R-200 - Drug Profile | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| R&D Progress | 50 | 1 |
| ranibizumab - Drug Profile | 51 | 1 |
| Product Description | 51 | 1 |
| Mechanism of Action | 51 | 1 |
| R&D Progress | 51 | 4 |
| Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| Recombinant Protein for Oncology and Ophthalmology - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| Small Molecule for Retinopathy of Prematurity - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 1 |
| Small Molecules to Inhibit Eya Tyrosine Phosphatase for Solid Tumors and Retinopathy - Drug Profile | 58 | 1 |
| Product Description | 58 | 1 |
| Mechanism of Action | 58 | 1 |
| R&D Progress | 58 | 1 |
| vatiquinone - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 3 |
| Retinopathy Recent Pipeline Updates | 62 | 13 |
| Retinopathy - Dormant Projects | 75 | 1 |
| Retinopathy Discontinued Products | 76 | 1 |
| Retinopathy Product Development Milestones | 77 | 1 |
| Featured News &Press Releases | 77 | 1 |
| Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants | 77 | 1 |
| Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities | 77 | 1 |
| Appendix | 78 | 2 |
| Methodology | 78 | 1 |
| Coverage | 78 | 1 |
| Secondary Research | 78 | 1 |
| Primary Research | 78 | 1 |
| Expert Panel Validation | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 79 | 1 |